Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.54 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.54 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | CASR | P41180 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 3/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19392968 | 1.00 | BRD4 (0.54) | BRD4CREBBPNISCHHPGDPARP1 | |
| Oxalic Acid SCHEMBL27480190 | 0.90 | CREBBP (0.50) | BRD4CREBBPNISCHHPGDPARP1 | |
| Diethylamine SCHEMBL9700350 | 0.88 | HPGD (0.49) | BRD4CREBBPNISCHHPGDPARP1 | |
| SCHEMBL8564064 | 0.77 | NISCH (0.46) | BRD4CREBBPNISCHHPGDPARP1 | |
| SCHEMBL15158184 | 0.77 | HPGD (0.48) | BRD4CREBBPNISCHHPGDPARP1 | |
| SCHEMBL8564068 | 0.77 | NISCH (0.46) | BRD4CREBBPNISCHHPGDPARP1 | |
| SCHEMBL1981682 | 0.77 | NISCH (0.46) | BRD4CREBBPNISCHHPGDPARP1 | |
| SCHEMBL15718086 | 0.76 | NISCH (0.49) | BRD4CREBBPNISCHHPGDPARP1 | |
| SCHEMBL214287 | 0.76 | NISCH (0.49) | BRD4CREBBPNISCHHPGDPARP1 | |
| SCHEMBL5165849 | 0.76 | NISCH (0.49) | BRD4CREBBPNISCHHPGDPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026087635-A1 | DIHYDRO BENZOXAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2026-04-30 | — | — | WO | disclosed |
| CN-121574131-A | Heterocyclic compounds for insect repellent | 勃林格殷格翰动物保健有限公司 | 2026-02-27 | — | — | CN | disclosed |
| CN-111763180-B | Benzazepine compounds, preparation method and pharmaceutical application thereof | 中国医学科学院药物研究所 | 2023-06-09 | — | — | CN | disclosed |
| CN-116249704-A | Heterocyclic compounds for insect repellent | 勃林格殷格翰动物保健美国公司 | 2023-06-09 | — | — | CN | disclosed |
| US-20230028644-A1 | Low Greenhouse Gas Fuel Compositions | BP OIL INTERNATIONAL LIMITED (GB) | 2023-01-26 | — | — | US | disclosed |
| US-11384057-B2 | Methods for preparing fuel additives | BP OIL INTERNATIONAL LIMITED (GB) | 2022-07-12 | — | — | US | disclosed |
| EP-3414305-B1 | FUEL COMPOSITIONS | BP OIL INT (GB) | 2022-06-15 | — | — | EP | disclosed |
| US-11339343-B2 | Methods for blending fuels | BP OIL INTERNATIONAL LIMITED (GB) | 2022-05-24 | — | — | US | disclosed |
| US-11332682-B2 | Methods for reducing oxidation | BP OIL INTERNATIONAL LIMITED (GB) | 2022-05-17 | — | — | US | disclosed |
| EP-3414303-B1 | USES OF ADDITIVES FOR DEMULSIFYING | BP OIL INT (GB) | 2022-01-26 | — | — | EP | disclosed |
| EP-0670831-A1 | QUINOXALINE DERIVATIVE AS ANTIDIABETIC AGENT | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-09-13 | — | — | EP | disclosed |
| WO-1995009159-A1 | QUINOXALINE DERIVATIVE AS ANTIDIABETIC AGENT | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1995-04-06 | — | — | WO | disclosed |
| EP-0511879-B1 | Pyrazine derivatives | OTSUKA PHARMA CO LTD (JP) | 1995-03-22 | — | — | EP | disclosed |
| EP-0511879-A1 | Pyrazine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-11-04 | — | — | EP | disclosed |
| EP-0509845-A1 | (+) and (-) enantiomers of 5-aliphatic-6-(benzoxazinyl- or benzothiazinyl)-2,3,4,5-tetrahydropyridazin-3-ones | ORTHO PHARMACEUTICAL CORPORATION (US) | 1992-10-21 | — | — | EP | disclosed |
| US-5081242-A | Cardiotonic and bronchodilator agents; phosphodiesterase inhibitors | ORTHO PHARMACEUTICAL CORPORATION (US) | 1992-01-14 | — | — | US | disclosed |
| EP-0368410-A2 | Optically active benzoxazines and bezothiazines and a process for their stereospecific preparation | GIST-BROCADES N.V. (NL) | 1990-05-16 | — | — | EP | disclosed |
| US-4766118-A | CARDIOTONIC AGENTS, PHOSPHODIESTERASE INHIBITORS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1988-08-23 | — | — | US | disclosed |
| EP-0272914-A2 | 6-Benzoxazinyl- and 6-benzothiazinyl-2,3,4,5-tetrahydropyridazin-3-ones | ORTHO PHARMACEUTICAL CORPORATION (US) | 1988-06-29 | — | — | EP | disclosed |
| US-4721784-A | MUSCLE RELAXANTS, BRONCHODILATOR AGENTS, CARDIOTONIC AGENTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1988-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11384057-B2 | Methods for preparing fuel additives | POLB, IDH2, TOP2B | BRD4 898/4885CREBBP 1130/4885NISCH 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.